Corvus Pharmaceuticals Q3 net loss more than doubles to $20.34 million

• Corvus Pharmaceuticals’ third-quarter 2026 net loss more than doubled year over year to $20.34 million.
• Research and development expenses more than doubled to $17.78 million due primarily to higher soquelitinib clinical trial and personnel costs.
• Cash, cash equivalents and marketable securities totaled $202.9 million at September 30, 2026, providing expected funding into the second quarter of 2028.
• Enrollment remained on track in soquelitinib’s registrational Phase 3 peripheral T-cell lymphoma and Phase 2 atopic dermatitis trials.
• Initial hidradenitis suppurativa trial data are expected in the first half of 2027; a Phase 2 asthma trial should begin by Q1 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Corvus Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611051601PRIMZONEFULLFEED9871641) on November 05, 2026, and is solely responsible for the information contained therein.